Skip to main content

Table 1 Baseline Characteristics of All Patients

From: First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer

Characteristic

No. of Patients (%) or Median (Range)

Gender

  

 Male

31

86%

 Female

5

14%

Median age, years

63

35–84

ECOG PS

  

 0

14

39%

 1

20

55%

 2

2

6%

Smoker

26

72%

Pathology

  

 SCLC

34

94%

 Mixed-SCLC

2

6%

Number of metastatic sites

  

 1

22

61%

 2

8

22%

 3–4

6

17%

Locations of metastases

  

 Brain

7

19%

 Liver

8

22%

 Thoracic

21

58%

 Bone

11

30%

 Other

10

28%

Previous treatment

4

11%

 Chemotherapy

4

/

 Radiation therapy

3

/

 Immunotherapy

0

/

  1. ECOG PS, Eastern Oncology Collaborative Group performance status; SCLC, small-cell lung cancer